Stock Ratings / Health Care / CHRS / financials

CRDL (52) CMPX (46) MOLN (50) HUMA (31) ⌘ Pro Terminal →

Coherus Oncology Inc. (CHRS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.90 -22.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.86

Coherus Oncology Inc. (CHRS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $138.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CHRS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Coherus Oncology Inc. (NASDAQ: CHRS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.90 (-22.55% 1D, market cap $138.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CHRS ranks #642 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CHRS compare to CRDL and CMPX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CHRS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDL (Cardiol Therapeutics Inc. (Class A)) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, CHRS leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CHRS?

▼

Per CHRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001512762), Coherus Oncology Inc. generated $0 in revenue, $168.0M in net income, and -$138.5M in free cash flow against $258.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.86 (-4.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CHRS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY CHRS SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 34.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.07-7.5% Next Q

Q2 (-2Q)

Grade D$0.99+2% Next Q

Q3 (-1Q)

Grade E$1.01-10.9% Next Q

Current

Grade D-$0.90-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CHRS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CHRS currently carries a cautious 36/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.95) forces dealer call-delta covering toward $2.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CHRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CHRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CHRS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.5%	$168.0M	-$138.5M	-45%
FY 2024	$4.00B	52%	-5%	$28.5M	-$20.4M	-45%
FY 2023	$4.00B	52%	-5.4%	-$237.9M	-$174.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CHRS)

✓Walkthrough of CHRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CHRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.15%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.90H $0.92L $0.82C $0.90VOL 2.19M

RES: $1.28SUP: $0.81SMA50: $1.20SMA200: $1.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CHRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CHRS Butterfly Map → + Track CHRS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CHRS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CHRS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CHRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CHRS)

Health Care Rank #642 of 1016 ⚔️ CRDL vs CHRS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CHRS vs. CRDL, CMPX, MOLN, HUMA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Coherus Oncology Inc. (CHRS) ranks #642 by composite RQD confidence (36/100, grade D-) and #619 by equity capitalization ($138.8M). Within this direct 5-issuer industry benchmark cohort, CHRS leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CHRS at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CHRS ACTIVE Coherus Oncology Inc.	D-	36/100	—	—	-35.0%	-22.55%	$138.8M	Benchmark Subject
CRDL Cardiol Therapeutics Inc. (Class A)	D+	52/100	—	—	—	0.00%	$141.2M	/crdl-vs-chrs →
CMPX Compass Therapeutics Inc.	D	46/100	—	—	-34.6%	-0.54%	$136.2M	/cmpx-vs-chrs →
MOLN Molecular Partners AG	D	50/100	—	—	—	-4.88%	$132.4M	/moln-vs-chrs →
HUMA Humacyte Inc.	E	31/100	—	-30.0%	-35.0%	-0.06%	$130.5M	/huma-vs-chrs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001512762

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Coherus Oncology Inc. (CHRS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $168.0M, operating cash flow of -$138.5M, and free cash flow of -$138.5M (-577.7% YoY). On the balance sheet, CHRS closed FY2025 with $258.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$168.0M	-$138.5M	-$138.5M	$258.3M	—
FY2024 (FY)	2024-12-31	$0	$28.5M	-$20.4M	-$20.4M	$448.5M	—
FY2023 (FY)	2023-12-31	$0	-$237.9M	-$174.9M	-$174.9M	—	—

3. CHRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CHRS compare to CRDL and CMPX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CHRS?

Where is CHRS trading relative to its 50-day, 200-day, and 52-week technical levels?

CHRS last traded at $0.90 (-22.55% on volume of 6,138,709 shares), positioning the stock -25.00% below its 50-day simple moving average ($1.20) and -41.18% below its 200-day simple moving average ($1.53). Across its 52-week range of $0.81 to $2.62, CHRS sits at the 5.0% percentile with a 14-day RSI of 34.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).

CHRS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Coherus Oncology Inc. (CHRS)?

In FY 2025 (10-K), CHRS converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CHRS RQD Cockpit CHRS 12M Forecast CHRS Earnings & Move CHRS Dividends & DRIP CHRS Insiders & 13F CHRS Whale Options CHRS Profit Sankey CHRS News & Why